Lista de obras - Kimmo Porkka - Dominio Público Uruguay

A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo

artículo científico publicado en 2002

A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).

artículo científico publicado en 2009

A tumor-homing peptide with a targeting specificity related to lymphatic vessels

artículo científico publicado en 2002

A6.02 Somatic mutations in clonally expanded CD8+T cells in patients with newly diagnosed rheumatoid arthritis

scholarly article by Tiina Kelkka et al published February 2016 in Annals of the Rheumatic Diseases

Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment

scientific article published on 01 October 2019

Acute lymphoblastic leukemia associated with RCSD1–ABL1 novel fusion gene has a distinct gene expression profile from BCR–ABL1 fusion

article

Allogeneic stem cell transplantation reverses the poor prognosis of CML patients with deletions in derivative chromosome 9

scientific article published on 01 January 2005

Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia

scientific article published on 14 June 2007

Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.

artículo científico publicado en 2016

Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3.

artículo científico publicado en 2014

Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT.

artículo científico publicado en 2015

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

artículo científico publicado en 2015

BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?

artículo científico publicado en 2011

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

artículo científico publicado en 2011

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

artículo científico publicado en 2013

Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia

artículo científico publicado en 2018

Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia.

artículo científico publicado en 2017

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile

artículo científico publicado en 2011

Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians.

artículo científico publicado en 2014

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

artículo científico publicado en 2009

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

artículo científico publicado en 2011

Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myelo

artículo científico publicado en 2008

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

artículo científico publicado en 2009

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

artículo científico publicado en 2019

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models

artículo científico publicado en 2017

Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia

scientific article published on 19 December 2018

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

artículo científico publicado en 2008

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).

artículo científico publicado en 2014

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

artículo científico publicado en 2014

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors

artículo científico publicado en 2017

Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia

artículo científico publicado en 2013

Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients

article

ERCC6L2 defines a novel entity within inherited acute myeloid leukemia

scientific article published on 01 April 2019

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

artículo científico publicado en 2017

Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML

scientific article published on 07 June 2019

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML

artículo científico publicado en 2016

Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy

artículo científico publicado en 2014

Enrichment of rare variants in population isolates: single AICDA mutation responsible for hyper-IgM syndrome type 2 in Finland

artículo científico publicado en 2016

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

artículo científico publicado en 2016

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

artículo científico publicado en 2011

Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells

artículo científico publicado en 2007

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

artículo científico publicado en 2015

Germline alterations in a consecutive series of acute myeloid leukemia

artículo científico publicado en 2018

HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.

artículo científico publicado en 2016

Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies

scientific article published on 02 April 2019

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

artículo científico publicado en 2022

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia

artículo científico publicado en 2016

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing

artículo científico publicado en 2017

Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

artículo científico publicado en 2014

Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL

scientific article published on 11 January 2019

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML

scholarly article by Oscar Brück et al published 20 June 2018 in Leukemia

Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival

artículo científico publicado en 2020

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

artículo científico publicado en 2010

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

artículo científico publicado en 2013

Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia

scientific article published on 15 April 2009

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

artículo científico publicado en 2016

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

artículo científico publicado en 2013

Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy

artículo científico publicado en 2013

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling

artículo científico publicado en 2016

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.

artículo científico publicado en 2017

Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.

artículo científico publicado en 2012

Killer-cell immunoglobulin-like receptor ligand compatibility in the outcome of Finnish unrelated donor hematopoietic stem cell transplantation.

artículo científico publicado en 2007

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.

artículo científico publicado en 2016

Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

artículo científico publicado en 2017

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy

artículo científico publicado en 2009

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

artículo científico publicado en 2016

Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS

artículo científico publicado en 2021

Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia

artículo científico publicado en 2016

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

artículo científico publicado en 2010

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

artículo científico publicado en 2020

NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib

artículo científico publicado en 2017

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia

artículo científico publicado en 2014

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

artículo científico publicado en 2015

Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation

artículo científico publicado en 2013

Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels

artículo científico publicado en 2003

Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia

artículo científico publicado en 2012

Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia

artículo científico publicado en 2007

Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients

artículo científico publicado en 2012

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

artículo científico publicado en 2011

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies

artículo científico publicado en 2014

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

artículo científico publicado en 2012

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia

artículo científico publicado en 2016

STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia

artículo científico publicado en 2012

Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

artículo científico publicado en 2016

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib

artículo científico

Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis.

artículo científico publicado en 2017

The EUTOS CML score aims to support clinical decision-making

scientific article published on 01 March 2012

The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia

artículo científico publicado en 2014

Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations

artículo científico

Lista de obras de Kimmo Porkka

A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo

A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).

A tumor-homing peptide with a targeting specificity related to lymphatic vessels

A6.02 Somatic mutations in clonally expanded CD8+T cells in patients with newly diagnosed rheumatoid arthritis

Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment

Acute lymphoblastic leukemia associated with RCSD1–ABL1 novel fusion gene has a distinct gene expression profile from BCR–ABL1 fusion

Allogeneic stem cell transplantation reverses the poor prognosis of CML patients with deletions in derivative chromosome 9

Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia

Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.

Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3.

Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT.

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia

Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia.

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile

Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians.

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myelo

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models

Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors

Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia

Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients

ERCC6L2 defines a novel entity within inherited acute myeloid leukemia

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML

Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy

Enrichment of rare variants in population isolates: single AICDA mutation responsible for hyper-IgM syndrome type 2 in Finland

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

Germline alterations in a consecutive series of acute myeloid leukemia

HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.

Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing

Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML

Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.

Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.

Killer-cell immunoglobulin-like receptor ligand compatibility in the outcome of Finnish unrelated donor hematopoietic stem cell transplantation.

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.

Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS

Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation

Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels

Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia

Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia

Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score